Why the study?
This study was conducted to assess the efficacy and safety of mavacamten in patients with hypertrophic cardiomyopathy.
Does mavacamten improve clinical and functional outcomes in patients with hypertrophic cardiomyopathy?
Does mavacamten improve clinical and functional outcomes in patients with hypertrophic cardiomyopathy?
Mavacamten improves symptoms, functional status, and LVOT gradients, and reduces the need for septal reduction therapy in patients with hypertrophic cardiomyopathy, without increasing severe adverse events.
Supports mavacamten to defer septal reduction in obstructive HCM; reinforces RCT evidence for practice and guidelines.
Aim: This meta-analysis was performed to assess the efficacy and safety of mavacamten in patients with hypertrophic cardiomyopathy. Methods & materials: A search was conducted using PubMed, Cochrane, and Scopus up to August 2022 for randomized studies reporting our pre-specified outcomes. Results: It was observed that mavacamten significantly improved New York Heart Association class (p < 0.009), Clinical Summary Score of the Kansas City Cardiomyopathy Questionnaire (p = 0.02), post-exercise left ventricular outflow tract gradient (p < 0.00001), functional end point (p = 0.05), and lowered septal reduction therapy rates (p < 0.00001). However, there were no significant differences in the ≥1 severe adverse events, ≥1 treatment-emergent adverse events, left ventricular volume index, left ventricular filling pressure, left ventricular end-diastolic volume index, and peak oxygen uptake (pVO2). Conclusion: Future large-scale trials are required to confirm our results and determine the long-term benefits and risks of mavacamten use in these patients.
No takes yet. Share an insight, caveat, or question.
Memon et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: